Xeris Biopharma Holdings (XERS) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $621000.0.
- Xeris Biopharma Holdings' Income towards Parent Company rose 10394.59% to $621000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 7521.91%. This contributed to the annual value of -$54.8 million for FY2024, which is 1191.71% up from last year.
- Latest data reveals that Xeris Biopharma Holdings reported Income towards Parent Company of $621000.0 as of Q3 2025, which was up 10394.59% from -$1.9 million recorded in Q2 2025.
- Xeris Biopharma Holdings' Income towards Parent Company's 5-year high stood at $621000.0 during Q3 2025, with a 5-year trough of -$50.8 million in Q4 2021.
- Over the past 5 years, Xeris Biopharma Holdings' median Income towards Parent Company value was -$16.8 million (recorded in 2023), while the average stood at -$18.2 million.
- Per our database at Business Quant, Xeris Biopharma Holdings' Income towards Parent Company crashed by 13237.41% in 2021 and then soared by 10394.59% in 2025.
- Over the past 5 years, Xeris Biopharma Holdings' Income towards Parent Company (Quarter) stood at -$50.8 million in 2021, then skyrocketed by 74.54% to -$12.9 million in 2022, then decreased by 3.56% to -$13.4 million in 2023, then surged by 61.81% to -$5.1 million in 2024, then surged by 112.15% to $621000.0 in 2025.
- Its Income towards Parent Company stands at $621000.0 for Q3 2025, versus -$1.9 million for Q2 2025 and -$9.2 million for Q1 2025.